{"id":8612,"date":"2025-08-19T04:51:11","date_gmt":"2025-08-19T04:51:11","guid":{"rendered":"https:\/\/www.europesays.com\/ie\/8612\/"},"modified":"2025-08-19T04:51:11","modified_gmt":"2025-08-19T04:51:11","slug":"eli-lillys-weight-loss-breakthroughs-face-brutal-investor-scrutiny-the-irish-times","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ie\/8612\/","title":{"rendered":"Eli Lilly\u2019s weight-loss breakthroughs face brutal investor scrutiny \u2013 The Irish Times"},"content":{"rendered":"<p class=\"c-paragraph paywall \"><a href=\"https:\/\/www.irishtimes.com\/tags\/eli-lilly\/\" target=\"_self\" rel=\"nofollow noopener\" title=\"https:\/\/www.irishtimes.com\/tags\/eli-lilly\/\">Eli Lilly<\/a>\u2019s latest earnings and trial results offered plenty to celebrate. Its orforglipron pill helped participants shed an average of 12.4 per cent of body weight, while preliminary data hinted at broader <a href=\"https:\/\/www.irishtimes.com\/health\/your-wellness\/\" target=\"_self\" rel=\"nofollow noopener\" title=\"https:\/\/www.irishtimes.com\/health\/your-wellness\/\">health benefits<\/a>. <\/p>\n<p class=\"c-paragraph paywall \">Revenues soared, guidance was raised, and the outlook looked strong.<\/p>\n<p class=\"c-paragraph paywall \">Yet investors severely punished America\u2019s most valuable <a href=\"https:\/\/www.irishtimes.com\/tags\/pharma\/\" target=\"_self\" rel=\"nofollow noopener\" title=\"https:\/\/www.irishtimes.com\/tags\/pharma\/\">pharma<\/a> stock. Shares sank 14 per cent, the steepest one-day drop in 25 years.<\/p>\n<p class=\"c-paragraph paywall \">The culprit? Side effects, notably nausea and vomiting, and weight loss outcomes that were slightly below the lofty expectations built into Lilly\u2019s valuation. In other words, perfection was priced in; anything less provoked panic.<\/p>\n<p class=\"c-paragraph paywall \">It illustrates the ferocity of the race in <a href=\"https:\/\/www.irishtimes.com\/tags\/obesity\/\" target=\"_self\" rel=\"nofollow noopener\" title=\"https:\/\/www.irishtimes.com\/tags\/obesity\/\">obesity drugs<\/a>. Shares in Denmark\u2019s <a href=\"https:\/\/www.irishtimes.com\/tags\/novo-nordisk\/\" target=\"_self\" rel=\"nofollow noopener\" title=\"https:\/\/www.irishtimes.com\/tags\/novo-nordisk\/\">Novo Nordisk<\/a>, the pioneer with its injectable <a href=\"https:\/\/www.irishtimes.com\/tags\/ozempic\/\" target=\"_self\" rel=\"nofollow noopener\" title=\"https:\/\/www.irishtimes.com\/tags\/ozempic\/\">Ozempic<\/a>, have lost two-thirds of their value as rivals nibble at its market. <\/p>\n<p class=\"c-paragraph paywall \">Weight-loss pills are the next frontier: easier to manufacture, distribute and more convenient for patients. But investors\u2019 appetite for blockbuster breakthroughs leaves little tolerance for anything short of spectacular.<\/p>\n<p class=\"c-paragraph b-it-article-body__interstitial-link\">[\u00a0<a aria-label=\"Open related story\" class=\"c-link\" href=\"https:\/\/www.irishtimes.com\/business\/2025\/08\/07\/eli-lilly-obesity-pill-disappoints-in-trial-sending-shares-down-14\/\" rel=\"noreferrer nofollow noopener\" target=\"_blank\">Eli Lilly obesity pill disappoints in trial, sending shares down 14%Opens in new window<\/a>\u00a0]<\/p>\n<p class=\"c-paragraph paywall \">Lilly is still worth over $500 billion, but its market capitalisation has shed almost a third in the past year. With competition intensifying, it\u2019s another reminder that valuations in weight-loss drugs may be losing weight of their own.<\/p>\n","protected":false},"excerpt":{"rendered":"Eli Lilly\u2019s latest earnings and trial results offered plenty to celebrate. Its orforglipron pill helped participants shed an&hellip;\n","protected":false},"author":2,"featured_media":8613,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[73],"tags":[79,18,1465,19,17,6526,7176,2927,2554],"class_list":{"0":"post-8612","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-business","8":"tag-business","9":"tag-eire","10":"tag-eli-lilly","11":"tag-ie","12":"tag-ireland","13":"tag-novo-nordisk","14":"tag-obesity","15":"tag-ozempic","16":"tag-pharma"},"share_on_mastodon":{"url":"","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/8612","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/comments?post=8612"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/8612\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media\/8613"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media?parent=8612"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/categories?post=8612"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/tags?post=8612"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}